Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KITE-363 in Refractory Autoimmune Diseases
NCT07038447Phase 1Enrolling by invitation
- Sponsor
- Kite Pharma
- Start
- Jul 2025
- Primary completion
- Sep 2030
- Modality
- CAR-T Cells
- Countries
- 4
01
Overview
Phase 1, open-label trial of KITE-363 in systemic lupus erythematosus (SLE), lupus nephritis (LN), systemic sclerosis (SSc) and 1 more (2 arms), sponsored by Kite Pharma. Primary endpoints: Dose-limiting Toxicities up to 2 years, Treatment-emergent Adverse Events up to 2 years and 5 more. Started Jul 2025; status: enrolling by invitation.
02
Drugs
KITE-363
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)systemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07038447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038447.